S6K1 Is Required for Increasing Skeletal Muscle Force during Hypertrophy

Cell Reports

Volumn 17, Issue 2, 2016, Pages 501-513

  Marabita, Manuela ^a   Baraldo, Martina ^a   Solagna, Francesca ^a   Ceelen, Judith Johanna Maria ^a   Sartori, Roberta ^a   Nolte, Hendrik ^b   Nemazanyy, Ivan ^d   Pyronnet, Stéphane ^c   Kruger, Marcus ^b   Pende, Mario ^d   Blaauw, Bert ^a,e  

^a VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^c UNIVERSITÉ DE TOULOUSE   (France)

^d INSTITUT NECKER ENFANTS MALADES   (France)

^e UNIVERSITY OF PADOVA   (Italy)

Author keywords

AKT; hypertrophy; mTOR; muscle force; p62; protein aggregates; rapamycin; S6K1; skeletal muscle

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN P62; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; S6K1 PROTEIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; EIF4EBP1 PROTEIN, MOUSE; ONCOPROTEIN; P62 PEPTIDE; PEPTIDE; PHOSPHOPROTEIN; PROTEIN AGGREGATE; RIBOSOMAL PROTEIN S6 KINASE, 70KD, POLYPEPTIDE 1; S6 KINASE; TARGET OF RAPAMYCIN KINASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOGENESIS; CONTROLLED STUDY; GENE DELETION; MOUSE; MUSCLE GROWTH; MUSCLE HYPERTROPHY; MUSCLE STRENGTH; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RIBOSOME; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; ANIMAL; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; HYPERTROPHY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SARCOPENIA;

ANIMALS; CARRIER PROTEINS; HUMANS; HYPERTROPHY; MICE; MICE, KNOCKOUT; MUSCLE, SKELETAL; ONCOGENE PROTEIN V-AKT; PEPTIDES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN AGGREGATES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RIBOSOMES; SARCOPENIA; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 85004000398     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.09.020     Document Type: Article

References (41)

1. Aguilar, V., Alliouachene, S., Sotiropoulos, A., Sobering, A., Athea, Y., Djouadi, F., Miraux, S., Thiaudière, E., Foretz, M., Viollet, B., et al. S6 kinase deletion suppresses muscle growth adaptations to nutrient availability by activating AMP kinase. Cell Metab. 5 (2007), 476–487.
2. Amthor, H., Macharia, R., Navarrete, R., Schuelke, M., Brown, S.C., Otto, A., Voit, T., Muntoni, F., Vrbóva, G., Partridge, T., et al. Lack of myostatin results in excessive muscle growth but impaired force generation. Proc. Natl. Acad. Sci. USA 104 (2007), 1835–1840.
3. Baar, K., Esser, K., Phosphorylation of p70(S6k) correlates with increased skeletal muscle mass following resistance exercise. Am. J. Physiol. 276 (1999), C120–C127.
4. Belin, S., Beghin, A., Solano-Gonzàlez, E., Bezin, L., Brunet-Manquat, S., Textoris, J., Prats, A.C., Mertani, H.C., Dumontet, C., Diaz, J.J., Dysregulation of ribosome biogenesis and translational capacity is associated with tumor progression of human breast cancer cells. PLoS ONE, 4, 2009, e7147.
5. Ben-Hur, V., Denichenko, P., Siegfried, Z., Maimon, A., Krainer, A., Davidson, B., Karni, R., S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Rep. 3 (2013), 103–115.
6. Ben-Sahra, I., Howell, J.J., Asara, J.M., Manning, B.D., Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 339 (2013), 1323–1328.
7. Blaauw, B., Mammucari, C., Toniolo, L., Agatea, L., Abraham, R., Sandri, M., Reggiani, C., Schiaffino, S., Akt activation prevents the force drop induced by eccentric contractions in dystrophin-deficient skeletal muscle. Hum. Mol. Genet. 17 (2008), 3686–3696.
8. Blaauw, B., Canato, M., Agatea, L., Toniolo, L., Mammucari, C., Masiero, E., Abraham, R., Sandri, M., Schiaffino, S., Reggiani, C., Inducible activation of Akt increases skeletal muscle mass and force without satellite cell activation. FASEB J. 23 (2009), 3896–3905.
9. Blaauw, B., Schiaffino, S., Reggiani, C., Mechanisms modulating skeletal muscle phenotype. Compr. Physiol. 3 (2013), 1645–1687.
10. Bodine, S.C., Stitt, T.N., Gonzalez, M., Kline, W.O., Stover, G.L., Bauerlein, R., Zlotchenko, E., Scrimgeour, A., Lawrence, J.C., Glass, D.J., Yancopoulos, G.D., Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 3 (2001), 1014–1019.
11. Burd, N.A., Holwerda, A.M., Selby, K.C., West, D.W., Staples, A.W., Cain, N.E., Cashaback, J.G., Potvin, J.R., Baker, S.K., Phillips, S.M., Resistance exercise volume affects myofibrillar protein synthesis and anabolic signalling molecule phosphorylation in young men. J. Physiol. 588 (2010), 3119–3130.
12. Chauvin, C., Koka, V., Nouschi, A., Mieulet, V., Hoareau-Aveilla, C., Dreazen, A., Cagnard, N., Carpentier, W., Kiss, T., Meyuhas, O., Pende, M., Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program. Oncogene 33 (2014), 474–483.
13. Conn, C.S., Qian, S.B., Nutrient signaling in protein homeostasis: an increase in quantity at the expense of quality. Sci. Signal., 6, 2013, ra24.
14. Drummond, D.A., Wilke, C.O., The evolutionary consequences of erroneous protein synthesis. Nat. Rev. Genet. 10 (2009), 715–724.
15. Fenton, T.R., Gout, I.T., Functions and regulation of the 70kDa ribosomal S6 kinases. Int. J. Biochem. Cell Biol. 43 (2011), 47–59.
16. Garelick, M.G., Mackay, V.L., Yanagida, A., Academia, E.C., Schreiber, K.H., Ladiges, W.C., Kennedy, B.K., Chronic rapamycin treatment or lack of S6K1 does not reduce ribosome activity in vivo. Cell Cycle 12 (2013), 2493–2504.
17. Goodman, C.A., Frey, J.W., Mabrey, D.M., Jacobs, B.L., Lincoln, H.C., You, J.S., Hornberger, T.A., The role of skeletal muscle mTOR in the regulation of mechanical load-induced growth. J. Physiol. 589 (2011), 5485–5501.
18. Hara, K., Maruki, Y., Long, X., Yoshino, K., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., Yonezawa, K., Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110 (2002), 177–189.
19. Huang, B.P., Wang, Y., Wang, X., Wang, Z., Proud, C.G., Blocking eukaryotic initiation factor 4F complex formation does not inhibit the mTORC1-dependent activation of protein synthesis in cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 296 (2009), H505–H514.
20. Kalista, S., Schakman, O., Gilson, H., Lause, P., Demeulder, B., Bertrand, L., Pende, M., Thissen, J.P., The type 1 insulin-like growth factor receptor (IGF-IR) pathway is mandatory for the follistatin-induced skeletal muscle hypertrophy. Endocrinology 153 (2012), 241–253.
21. Kirby, T.J., Lee, J.D., England, J.H., Chaillou, T., Esser, K.A., McCarthy, J.J., Blunted hypertrophic response in aged skeletal muscle is associated with decreased ribosome biogenesis. J. Appl. Physiol. 119 (2015), 321–327.
22. Le Bacquer, O., Petroulakis, E., Paglialunga, S., Poulin, F., Richard, D., Cianflone, K., Sonenberg, N., Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J. Clin. Invest. 117 (2007), 387–396.
23. Masiero, E., Agatea, L., Mammucari, C., Blaauw, B., Loro, E., Komatsu, M., Metzger, D., Reggiani, C., Schiaffino, S., Sandri, M., Autophagy is required to maintain muscle mass. Cell Metab. 10 (2009), 507–515.
24. McMullen, J.R., Shioi, T., Zhang, L., Tarnavski, O., Sherwood, M.C., Dorfman, A.L., Longnus, S., Pende, M., Martin, K.A., Blenis, J., et al. Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. Mol. Cell. Biol. 24 (2004), 6231–6240.
25. Ohanna, M., Sobering, A.K., Lapointe, T., Lorenzo, L., Praud, C., Petroulakis, E., Sonenberg, N., Kelly, P.A., Sotiropoulos, A., Pende, M., Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat. Cell Biol. 7 (2005), 286–294.
26. Orsolic, I., Jurada, D., Pullen, N., Oren, M., Eliopoulos, A.G., Volarevic, S., The relationship between the nucleolus and cancer: current evidence and emerging paradigms. Semin. Cancer Biol. 37-38 (2016), 36–50.
27. Pallafacchina, G., Calabria, E., Serrano, A.L., Kalhovde, J.M., Schiaffino, S., A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification. Proc. Natl. Acad. Sci. USA 99 (2002), 9213–9218.
28. Pankiv, S., Clausen, T.H., Lamark, T., Brech, A., Bruun, J.A., Outzen, H., Øvervatn, A., Bjørkøy, G., Johansen, T., p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J. Biol. Chem. 282 (2007), 24131–24145.
29. Pende, M., Kozma, S.C., Jaquet, M., Oorschot, V., Burcelin, R., Le Marchand-Brustel, Y., Klumperman, J., Thorens, B., Thomas, G., Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature 408 (2000), 994–997.
30. Pende, M., Um, S.H., Mieulet, V., Sticker, M., Goss, V.L., Mestan, J., Mueller, M., Fumagalli, S., Kozma, S.C., Thomas, G., S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol. Cell. Biol. 24 (2004), 3112–3124.
31. Rommel, C., Bodine, S.C., Clarke, B.A., Rossman, R., Nunez, L., Stitt, T.N., Yancopoulos, G.D., Glass, D.J., Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3 (2001), 1009–1013.
32. Sartori, R., Schirwis, E., Blaauw, B., Bortolanza, S., Zhao, J., Enzo, E., Stantzou, A., Mouisel, E., Toniolo, L., Ferry, A., et al. BMP signaling controls muscle mass. Nat. Genet. 45 (2013), 1309–1318.
33. Schiaffino, S., Dyar, K.A., Ciciliot, S., Blaauw, B., Sandri, M., Mechanisms regulating skeletal muscle growth and atrophy. FEBS J. 280 (2013), 4294–4314.
34. Shioi, T., McMullen, J.R., Tarnavski, O., Converso, K., Sherwood, M.C., Manning, W.J., Izumo, S., Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 107 (2003), 1664–1670.
35. Steiner, J.L., Pruznak, A.M., Deiter, G., Navaratnarajah, M., Kutzler, L., Kimball, S.R., Lang, C.H., Disruption of genes encoding eIF4E binding proteins-1 and -2 does not alter basal or sepsis-induced changes in skeletal muscle protein synthesis in male or female mice. PLoS ONE, 9, 2014, e99582.
36. Terzis, G., Georgiadis, G., Stratakos, G., Vogiatzis, I., Kavouras, S., Manta, P., Mascher, H., Blomstrand, E., Resistance exercise-induced increase in muscle mass correlates with p70S6 kinase phosphorylation in human subjects. Eur. J. Appl. Physiol. 102 (2008), 145–152.
37. Tothova, J., Blaauw, B., Pallafacchina, G., Rudolf, R., Argentini, C., Reggiani, C., Schiaffino, S., NFATc1 nucleocytoplasmic shuttling is controlled by nerve activity in skeletal muscle. J. Cell Sci. 119 (2006), 1604–1611.
38. Wenger, T., Terawaki, S., Camosseto, V., Abdelrassoul, R., Mies, A., Catalan, N., Claudio, N., Clavarino, G., de Gassart, A., Rigotti, Fde.A., et al. Autophagy inhibition promotes defective neosynthesized proteins storage in ALIS, and induces redirection toward proteasome processing and MHCI-restricted presentation. Autophagy 8 (2012), 350–363.
39. Winbanks, C.E., Weeks, K.L., Thomson, R.E., Sepulveda, P.V., Beyer, C., Qian, H., Chen, J.L., Allen, J.M., Lancaster, G.I., Febbraio, M.A., et al. Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin. J. Cell Biol. 197 (2012), 997–1008.
40. Winbanks, C.E., Chen, J.L., Qian, H., Liu, Y., Bernardo, B.C., Beyer, C., Watt, K.I., Thomson, R.E., Connor, T., Turner, B.J., et al. The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. J. Cell Biol. 203 (2013), 345–357.
41. Yanagiya, A., Suyama, E., Adachi, H., Svitkin, Y.V., Aza-Blanc, P., Imataka, H., Mikami, S., Martineau, Y., Ronai, Z.A., Sonenberg, N., Translational homeostasis via the mRNA cap-binding protein, eIF4E. Mol. Cell 46 (2012), 847–858.